Key Insights

Highlights

Treatment Research

1 treatments under study, led by Gnc038

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 1/2 (1)

Trial Status

Active Not Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT05627856Phase 1/2Active Not Recruiting

A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL

Showing all 1 trials

Research Network

Common Treatments

  • Gnc0381

Active Sponsors

  • Sichuan Baili Pharmaceutical Co., Ltd.1
  • SystImmune Inc.1
  • Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.1

Top Investigators

Related Conditions

  • Nonhodgkin Lymphoma1
  • Nkt Cell Lymphoma1

Activity Timeline